Entospletinib,Lanraplenib
Kronos Bio,gilead
[]
kronos bio continues to advance investigational syk inhibitors entospletinib and lanraplenib with new preclinical data at eha2022 congress - include preclinical data on syk inhibition in combination with targeted agents suggesting evidence of preclinica... 
CEO Of Digital Media Online